Koji Tamada
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (17)
We investigated immunologic biomarkers that predict outcomes of patients with previously treated metastatic non‐small cell lung cancer who were enrolled in the J‐TAIL study, a prospective, observational study of atezolizumab monotherapy. Of 262 patients participating in the J‐TAIL exploratory study, peripheral blood mononuclear cells were obtained from 51 patients and analyzed by T‐cell fractionation analysis using Helios mass cytometry and serum proteomics analysis. Following treatment with atezolizumab, an increase in programmed cell death‐1 (PD‐1)‐expressing CD8 and CD4 T‐cell populations was observed. A more pronounced increase in PD‐1 expression was seen in T cells from patients whose progression‐free survival (PFS) was 100 days or longer compared with those with shorter PFS. The proximity extension assay, which is highly sensitive multiplex analysis technology that combines antibody‐based affinity assays with next‐generation sequencing, showed a significant increase in FOXO1, possibly in response to precursor‐exhausted T‐cell population activation. Immune‐related adverse events were associated with a high percentage of PD‐1‐positive cells on effector memory CD8 T cells, which was thought to be accompanied by extremely high CD8 T‐cell activation. Further analysis distinguished poor prognosis populations with significant differences in CD62L high Th7R and CXCR3 + component of Th7R (CXCR3 + Th7R) within the population with PFS < 50 days. Patients with low Th7R or CXCR3 + Th7R percentages prior to atezolizumab treatment had significantly poorer overall survival. These findings provide valuable insights regarding T‐cell kinetics and biomarkers in atezolizumab therapy and may offer promising directions for future research. Trial Registration: UMIN Clinical Trials Registry: UMIN000033133 and UMIN000035567; ClinicalTrials.gov : NCT03645330
Year:
2026
In vitro responses of autologous Conv. and 7 × 19 CAR-T against patient-derived pancreatic cancer organoids. A, Surface expression of endogenous HER2 was assessed in patient-derived pancreatic cancer organoids by flow cytometry. Open and filled histograms indicate staining with humanized anti-HER2 Ab and nonstaining, followed by anti–human IgG Ab, respectively. B–D, Anti-HER2 Conv. or 7 × 19 CAR-T or UTD was cocultured with HER2-positive pancreatic cancer organoids at an effector to target (E:T) ratio of 1:1 for 4 days. B, Morphologic images after 4 days of coculture. C, The number of residual tumor cells after coculture was analyzed by flow cytometry. Data are shown as mean ± SD of triplicate samples. D, The supernatants were harvested after 4 days of coculture, and the concentration of IFNγ was assessed by ELISA. Data are shown as mean ± SD of triplicate samples. **, P P
Year:
2024
The diversity of TCR repertoire in T cells before and after the injection of 7 × 19 CAR-T. 7 × 19 CAR-T cells generated from PBMC were sorted into CAR-positive or -negative T cells and analyzed for repertoire of TCRα and TCRβ chains (before injection). Spleen cells were harvested from the mice which rejected U87MG EGFRvIII by the injection of anti-EGFRvIII 7 × 19 CAR, 42 days after tumor inoculation. Spleen cells were sorted into CAR-positive or -negative T cells for analysis of TCRα- and TCRβ-chain repertoire (after injection). TCR repertoire was analyzed using the next-generation sequencer, and the frequencies of V and J region usage were displayed as 3D graphs. The numbers in the graphs represent the diversity index calculated as Shannon–Weaver index H (a lower number indicates a less diversity). Representative data from three samples per group are shown.
Year:
2024
Potent therapeutic effects of patient’s PBMC-derived 7 × 19 CAR-T in autologous pancreatic cancer organoids. A, Tumor mass was established in NOG-ΔMHC by subcutaneous inoculation with 1 × 10 6 pancreatic cancer organoids. After 88 days, the established tumor mass was resected and examined for HER2 expression by IHC staining. B and C, NOG-ΔMHC mice were inoculated subcutaneously with 1 × 10 6 pancreatic cancer organoids on day 0 and then treated with intravenous injection of 5 × 10 6 anti-HER2 Conv. CAR-T or 7 × 19 CAR-T cells on day 10 or (left) untreated. Thereafter, the tumor size ( B ) and the mouse survival ( C ) were assessed ( n = 5 each in all groups, biological replicates). **, P P
Year:
2024
Potent therapeutic effects of 7 × 19 CAR-T in the preestablished solid tumor model of human glioblastoma. NOG-ΔMHC mice were inoculated subcutaneously with 3.5 × 10 6 U87MG EGFRvIII tumor cells on day 0 and then treated with intravenous injection of 1 × 10 7 Conv. CAR-T, 7 × 19 CAR-T, or UTD on day 10. Thereafter, the tumor size ( A ) and the mouse survival ( B ) were assessed ( n = 12 each in UTD and 7 × 19 CAR-T groups; n = 13 in Conv. CAR-T group; n values are biological replicates). In A , each line indicates the tumor volume of an individual mouse. Tumor volumes during the initial 56 days of 7 × 19 CAR-T–treated mice are shown in the inset. ***, P
Year:
2024
Massive infiltration of T cells and tumor cell lysis in the tumor tissues by the treatment with 7 × 19 CAR‐T. NOG‐ΔMHC mice were inoculated subcutaneously with 3.5 × 10 6 U87MG EGFRvIII cells on day 0, followed by intravenous injection of 1 × 10 7 UTD, Conv. CAR‐T, or 7 × 19 CAR‐T cells on day 10. Tumor tissues were resected from the mice on day 13 to prepare formalin-fixed, paraffin-embedded slices for H&E and IHC staining using rabbit anti–human CD4, CD8, CCR7, caspase-3 mAbs and mouse anti–human EGFRvIII mAb. Stained cells were visualized and observed by microscopic examinations at ×100 and ×400 magnifications. A, Representative images are displayed. Scale bar indicates a length of 200 μm (×100) or 50 μm (×400). B, The number of stained cells per tumor area (mm 2 ) or the percentage of the stained area was calculated using BZ‐X analyzer software. Data are shown as mean ± SD of triplicate samples ( n = 3 each per group, biological replicates). *, P P P
Year:
2024
EGFRvIII-specific immune responses of Conv. CAR and 7 × 19 CAR-T cells in vitro . A, Surface expression of EGFRvIII was assessed in U87MG glioblastoma cell lines by flow cytometry. Open and filled histograms indicate staining with anti-EGFRvIII Ab and nonstaining, followed by anti–mouse IgG Ab, respectively. B and C, Conv. CAR-T, 7 × 19 CAR-T, or UTD T cells were cocultured with the indicated tumor cells at an effector-to-target (E:T) ratio of 1:1 and 1:5 for 2 days. The number of residual tumor cells ( B ) and T cells ( C ) after coculture was analyzed by flow cytometry. Data are shown as mean ± SD of triplicate samples. D, The supernatants of the coculture described in B were harvested, and the concentration of IFNγ was assessed by ELISA. Data are shown as mean ± SD of triplicate samples. **, P P
Year:
2024
Cancer immunotherapy using immune checkpoint inhibitors and its combination with other anticancer therapies has emerged as a new standard of care because of the encouraging therapeutic effects in various solid cancers. Nonetheless, glioblastoma and pancreatic cancer remain resistant to immunotherapy and represent intractable cancers with the poorest prognosis. We investigated the therapeutic effects of next-generation chimeric antigen receptor (CAR) T cells producing IL7 and chemokine (C–C motif) ligand 19 (CCL19; referred to as 7 × 19 CAR-T) in these intractable cancers. Cytotoxic activities and therapeutic effects of 7 × 19 CAR-T were evaluated in vitro and in vivo , in a model using EGFR variant III (EGFRvIII)–positive glioblastoma and anti-EGFRvIII CAR-T generated from healthy donor peripheral blood mononuclear cells (PBMC), or a model using HER2-positive pancreatic cancer organoids and anti-HER2 CAR-T generated from the same patient’s PBMC. Anti-EGFRvIII 7 × 19 CAR-T exhibited cytotoxic activity specific to EGFRvIII-positive tumor, induced complete rejection of glioblastoma with massive T-cell infiltration and tumor cell death in the tumor tissues, and consequently prolonged mouse survival. Anti-HER2 7 × 19 CAR-T demonstrated a potent cytotoxic activity against autologous HER2-positive pancreatic cancer organoids and induced complete rejection of autologous tumor along with prolonged mouse survival. Our results suggest that 7 × 19 CAR-T could become a therapeutic option for glioblastoma and pancreatic cancer. To the best of our knowledge, this is the first study to demonstrate the therapeutic efficacy of next-generation CAR-T in an autologous model using patient-derived tumor organoids and CAR-T generated from the same patient’s PBMC, in which unwanted allogeneic immune responses are fully excluded. Significance: Despite the clinical development of CAR T-cell therapy, its efficacy in solid cancers has yet to be established. This study explored the therapeutic potential and immunologic mechanisms of IL7/CCL19-producing CAR-T therapy in preclinical solid cancer models of glioblastoma and pancreatic cancer. We found that IL7/CCL19-producing CAR-T cells generated from the patient’s PBMC showed potent therapeutic effects against the solid cancer model established by inoculating organoids from the autologous tumor tissue.
Year:
2024
The diversity of TCR repertoire in T cells before and after the injection of 7 × 19 CAR-T. 7 × 19 CAR-T cells generated from PBMC were sorted into CAR-positive or -negative T cells and analyzed for repertoire of TCRα and TCRβ chains (before injection). Spleen cells were harvested from the mice which rejected U87MG EGFRvIII by the injection of anti-EGFRvIII 7 × 19 CAR, 42 days after tumor inoculation. Spleen cells were sorted into CAR-positive or -negative T cells for analysis of TCRα- and TCRβ-chain repertoire (after injection). TCR repertoire was analyzed using the next-generation sequencer, and the frequencies of V and J region usage were displayed as 3D graphs. The numbers in the graphs represent the diversity index calculated as Shannon–Weaver index H (a lower number indicates a less diversity). Representative data from three samples per group are shown.
Year:
2024
EGFRvIII-specific immune responses of Conv. CAR and 7 × 19 CAR-T cells in vitro . A, Surface expression of EGFRvIII was assessed in U87MG glioblastoma cell lines by flow cytometry. Open and filled histograms indicate staining with anti-EGFRvIII Ab and nonstaining, followed by anti–mouse IgG Ab, respectively. B and C, Conv. CAR-T, 7 × 19 CAR-T, or UTD T cells were cocultured with the indicated tumor cells at an effector-to-target (E:T) ratio of 1:1 and 1:5 for 2 days. The number of residual tumor cells ( B ) and T cells ( C ) after coculture was analyzed by flow cytometry. Data are shown as mean ± SD of triplicate samples. D, The supernatants of the coculture described in B were harvested, and the concentration of IFNγ was assessed by ELISA. Data are shown as mean ± SD of triplicate samples. **, P P
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (3)
Hiroyuki Yasuda
Keio University
Hiroaki Nagano
-
Tetsuya Mitsudomi
Professor
Kindai University
Make your next move.
Prepare your application
Review drafts before you send them.